国药集团：药材股份已构成严重侵权，目前已启动法律程序

Core Viewpoint - China National Pharmaceutical Group (Sinopharm Group) has issued a statement regarding its severed ties with China Medicine Holdings Co., Ltd. (China Medicine), emphasizing that it has initiated legal proceedings against China Medicine for serious infringement of its rights [1][4]. Group 1: Company Relationship and Legal Actions - Sinopharm Group's subsidiary, China Medicine, has transferred its 25% stake in China Medicine Holdings to Shanghai Tianyue Tenghua Trading Service Co., Ltd., and will complete the deregistration of this stake by September 30, 2025 [3][4]. - Following the transfer, China Medicine will no longer hold any equity in China Medicine Holdings, and there will be no equity or control relationship between Sinopharm Group, China Medicine, and China Medicine Holdings [4]. - Sinopharm Group has never authorized China Medicine Holdings or its subsidiaries to use its trademarks or engage in activities under its name, and it will pursue legal action against any unauthorized use of its name or trademarks [4][5]. Group 2: Historical Context and Company Status - Sinopharm Group has previously issued multiple statements condemning China Medicine Holdings for unauthorized use of its name and trademarks, as well as for engaging in unfair competition and other legal disputes [5][7]. - China Medicine Holdings, originally named Huahao Pharmaceutical Co., Ltd., was established in 2000 with a registered capital of 100.58 million RMB and currently has multiple negative labels, including operational abnormalities and being a subject of enforcement actions [5][6]. - As of 2023 and 2024, China Medicine Holdings has reported zero employees enrolled in social insurance, indicating potential operational challenges [5][6].